CD44 and neoplasm: Our data show that, although the percentage of Tem cells (CD62L‐CD44+) in the Y45 and YD treatment groups remained comparable in the B16F10 tumor microenvironment, the YD‐treated group exhibited a broad enhancement of cytotoxic activity across all CD8+ subsets, including Tcm cells (Figure 7F).